Month: February 2025

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants...

VAL-D’OR, Quebec, Feb. 27, 2025 (GLOBE NEWSWIRE) — Cartier Resources Inc. (″Cartier″ or the ″Company″) (TSXV: ECR; FSE:6CA) is pleased to announce it has launched the Artificial Intelligence (″AI″) Targeting Program on the Cadillac Project, in the Val-d’Or mining camp (Quebec). The program incorporates VRIFY’s cutting-edge AI-Assisted Mineral Discovery Platform. VRIFY uses advanced AI and proprietary algorithms to generate a prospectivity score — known as a VRIFY Prospectivity Score (VPS) — that identifies areas for potential of gold mineralization. The VPS and models generated through the AI-Assisted Mineral Discovery Platform incorporate probabilistic values, which help to determine the accuracy and reliability of the predictions. Philippe Cloutier, President & CEO, stated: ″We are very excited to partner with the VRIFY...

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX – V: NBLC) (the “Company” or “Nobel”) is pleased to announce that its common shares (the “Nobel Shares”) will recommence trading on the TSX Venture Exchange (“TSXV”) on March 3, 2025. Trading of the Nobel Shares on the TSXV has been halted since the Company announced it had entered into option agreements to acquire a Chilean copper portfolio in Antofagasta Region, Chile (the “Transaction”). Please refer to the Company’s press release dated January 6, 2025 for further details regarding the Transaction. The Company has submitted a draft NI 43-101 technical report for the Cuprita project, the cornerstone property in the Transaction, to the TSXV and is working to satisfy the TSXV’s conditions to close the Transaction. About Nobel Nobel Resources is a Canadian resource...

– Company Expands Exports to Overseas Medical Cannabis Market with Top-Selling Pink Kush Cultivar – VANCOUVER, British Columbia, Feb. 27, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced its first shipment to New Zealand through its wholly-owned subsidiary Pure Sunfarms. The shipment features Pink Kush, the top-selling dried flower strain over the past four years1 in Canada, the largest federally legal market in the world. Pink Kush, along with a portfolio of our globally recognized strains, will be distributed in New Zealand by Medleaf Therapeutics (“Medleaf”) under its the ‘Bloom’ brand, created specifically for products from Pure Sunfarms. Medleaf is an established New Zealand-based medical cannabis company with a comprehensive distribution network, collaborating...

The POET Optical Interposer™ earns its 4th prestigious honor in less than a year TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (TSX Venture: PTK; NASDAQ: POET), a leader in the design and implementation of highly integrated optical engines and light sources for Artificial Intelligence networks, today announced that it was the recipient of another prestigious award. Lightwave+BTR Innovation Reviews, a recognized authority in the optoelectronics industry, named POET as an Elite Score recipient for its 2025 awards. The publication, which recognizes excellence in a product or technology applicable to optical networks, singled out the POET Optical Interposer™ for the honor. A panel of judges, comprised of experts from the optical communications and broadband...

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio® (abemaciclib) established –  – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that Li-Cycle Holdings Corp. (OTCQX: LICYF), a leading global lithium-ion battery resource recovery company, has qualified to trade on the OTCQX® Best Market. Li-Cycle Holdings Corp. previously traded on the New York Stock Exchange. Li-Cycle Holdings Corp. begins trading today on OTCQX under the symbol “LICYF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly...

Achieves milestone production during week-long operation; optimization testing to continue MONTREAL, Feb. 27, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today that, further to HPQ Silicon Inc’s (“HPQ”) press release dated today, and PyroGenesis’ own news releases dated February 6, 2024 and March 12, 2024, the next milestone for the fumed silica reactor (“FSR”) pilot plant has been reached, with its successful week-long operation and the production of the first batch of materials. This initial...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2024, as well as business updates. “In 2024, C4T made significant progress across our degrader portfolio and our discovery collaborations....

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102 has been well-tolerated, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed Delivery of opt-in package to Eli Lilly and an opt-in decision from Lilly expected in the second half of 2025 Enrollment ongoing in Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 Cash, cash equivalents, and marketable securities of $524.3 million; cash runway into mid-2027 BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today reported pipeline and corporate updates and financial results...